Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis.
calcineurin inhibitor
epidemiology
inflammatory bowel disease
surgery
ulcerative colitis
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
18 10 2021
18 10 2021
Historique:
received:
15
08
2020
pubmed:
16
12
2020
medline:
15
2
2022
entrez:
15
12
2020
Statut:
ppublish
Résumé
Inpatient management of severe ulcerative colitis is complicated by the use of prior immunosuppressant therapies. Our aim was to determine the rate of 1-year colectomy among individuals receiving inpatient calcineurin inhibitor (CNI)-based therapy stratified by prior biologic therapy. A retrospective cohort study was performed between January 1, 2013 and April 1, 2018. Only individuals requiring inpatient administration of intravenous cyclosporine or oral tacrolimus were included in the analysis. Individuals were stratified according to prior biologic therapy exposure. The primary outcome of interest was 1-year risk of colectomy. Kaplan-Meier curves were generated for time-to-event data, and regression models were performed to examine the effects of covariates on the clinical endpoint. Sixty-nine (62.3% male) patients were treated with an inpatient CNI-based therapy and were included in the analysis. Fifteen (21.7%) patients were biologic-naïve, 42 (60.9%) patients had prior exposure to 1 class of biologic therapy, and 12 (17.4%) patients had prior exposure to 2 classes of biologic therapy (third-line CNI therapy). Third-line CNI therapy showed a greater risk of 1-year colectomy risk when compared with the risk for patients who were biologic-naïve (hazard ratio, 3.63; 95% confidence interval, 1.17-13.45; P = 0.025). In a multivariate proportional hazards model, third-line CNI therapy remained significantly associated with 1-year colectomy risk (hazard ratio, 7.94; 95% confidence interval, 1.97-39.76; P = 0.003). The use of CNI-based therapy in individuals exposed to multiple classes of prior biologic therapies leads to a significantly increased risk of 1-year colectomy. Future studies will be required to compare inpatient management strategies with the expanding novel therapies in UC.
Sections du résumé
BACKGROUND
Inpatient management of severe ulcerative colitis is complicated by the use of prior immunosuppressant therapies. Our aim was to determine the rate of 1-year colectomy among individuals receiving inpatient calcineurin inhibitor (CNI)-based therapy stratified by prior biologic therapy.
METHODS
A retrospective cohort study was performed between January 1, 2013 and April 1, 2018. Only individuals requiring inpatient administration of intravenous cyclosporine or oral tacrolimus were included in the analysis. Individuals were stratified according to prior biologic therapy exposure. The primary outcome of interest was 1-year risk of colectomy. Kaplan-Meier curves were generated for time-to-event data, and regression models were performed to examine the effects of covariates on the clinical endpoint.
RESULTS
Sixty-nine (62.3% male) patients were treated with an inpatient CNI-based therapy and were included in the analysis. Fifteen (21.7%) patients were biologic-naïve, 42 (60.9%) patients had prior exposure to 1 class of biologic therapy, and 12 (17.4%) patients had prior exposure to 2 classes of biologic therapy (third-line CNI therapy). Third-line CNI therapy showed a greater risk of 1-year colectomy risk when compared with the risk for patients who were biologic-naïve (hazard ratio, 3.63; 95% confidence interval, 1.17-13.45; P = 0.025). In a multivariate proportional hazards model, third-line CNI therapy remained significantly associated with 1-year colectomy risk (hazard ratio, 7.94; 95% confidence interval, 1.97-39.76; P = 0.003).
CONCLUSIONS
The use of CNI-based therapy in individuals exposed to multiple classes of prior biologic therapies leads to a significantly increased risk of 1-year colectomy. Future studies will be required to compare inpatient management strategies with the expanding novel therapies in UC.
Identifiants
pubmed: 33319248
pii: 6034840
doi: 10.1093/ibd/izaa326
pmc: PMC8682443
doi:
Substances chimiques
Biological Products
0
Calcineurin Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1620-1625Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK042086
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK084725
Pays : United States
Organisme : Gastrointestinal Research Foundation
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Therap Adv Gastroenterol. 2018 May 08;11:1756284818772786
pubmed: 29774052
Clin Gastroenterol Hepatol. 2019 Feb;17(3):494-501
pubmed: 30213584
Clin Gastroenterol Hepatol. 2019 Apr;17(5):988-990.e1
pubmed: 30458248
J Crohns Colitis. 2019 Sep 19;13(9):1105-1110
pubmed: 30726894
J Clin Pharmacol. 1991 Jan;31(1):76-80
pubmed: 2045532
Clin Gastroenterol Hepatol. 2019 Feb;17(3):486-493
pubmed: 29751166
Inflamm Bowel Dis. 2014 Jan;20(1):103-14
pubmed: 24280881
J Crohns Colitis. 2019 May 27;13(6):744-754
pubmed: 30916775
Inflamm Bowel Dis. 2019 Jun 18;25(7):1169-1186
pubmed: 30605549
Br Med J. 1954 Aug 14;2(4884):375-8
pubmed: 13182220
World J Gastroenterol. 2019 Apr 7;25(13):1603-1617
pubmed: 30983820
Lancet Gastroenterol Hepatol. 2016 Sep;1(1):15-24
pubmed: 27595142
J Crohns Colitis. 2014 Nov;8(11):1427-37
pubmed: 24908178
Aliment Pharmacol Ther. 2020 Jun;51(11):1039-1046
pubmed: 32291786
N Engl J Med. 1994 Jun 30;330(26):1841-5
pubmed: 8196726
Aliment Pharmacol Ther. 2020 Mar;51(6):637-643
pubmed: 31875986
J Crohns Colitis. 2010 Oct;4(4):431-7
pubmed: 21122540
Gut. 1998 Jul;43(1):29-32
pubmed: 9771402
Clin Gastroenterol Hepatol. 2020 Dec;18(13):2952-2961.e8
pubmed: 32062041
Lancet. 2012 Dec 1;380(9857):1909-15
pubmed: 23063316
Mayo Clin Proc. 1992 Oct;67(10):981-90
pubmed: 1434859
Intest Res. 2015 Jul;13(3):219-26
pubmed: 26130996
Aliment Pharmacol Ther. 2020 May;51(9):880-888
pubmed: 32237087
Am J Gastroenterol. 2019 Mar;114(3):384-413
pubmed: 30840605
N Engl J Med. 1987 Dec 24;317(26):1625-9
pubmed: 3317057
Am J Gastroenterol. 1999 Jun;94(6):1587-92
pubmed: 10364029